Shopping Cart
- Remove All
- Your shopping cart is currently empty
CG-200745 is a potent inhibitor of HDAC. CG200745 induces apoptosis and also inhibits the deacetylation of histone H3 and tubulin.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 6-8 weeks | |
50 mg | $2,180 | 6-8 weeks | |
100 mg | $2,800 | 6-8 weeks |
Description | CG-200745 is a potent inhibitor of HDAC. CG200745 induces apoptosis and also inhibits the deacetylation of histone H3 and tubulin. |
In vitro | CG200745 induces the accumulation of p53. It promotes p53-dependent transactivation, and it also enhances the expression of MDM2 and p21 (Waf1/Cip1) proteins [1,2]. CG-200745 (0-10 μM; 48 hours) reduces the Calu6 cells proliferation to 40% of untreated cells. CG-200745 (0-10 μM; 1-24 hours) treatment with low concentration significantly increases the acetylation of histone H3 and H4 in Calu6 cells at various sites in a time-dependent manner up to 24 hours after treatment. CG-200745 (3 μM; 1-24 hours) significantly increases Calu6 cells proportion in the G2/M phase (69%) [3]. |
In vivo | CG-200745 (p.o.; 30?mg/kg/day; for 7 days) weaken inflammatory cytokines, adhesion molecules, oxidative stress in UUO kidneys [4]. |
Alias | CG-200745 |
Molecular Weight | 427.54 |
Formula | C24H33N3O4 |
Cas No. | 936221-33-9 |
Relative Density. | 1.148±0.06 g/cm3 (20 °C, 760 mmHg) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.